Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$6.70 USD
-0.19 (-2.76%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $6.70 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LYRA 6.70 -0.19(-2.76%)
Will LYRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LYRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LYRA
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
LYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates
Other News for LYRA
Lyra Therapeutics registers shares for resale from warrant exercises
Lyra Therapeutics (LYRA) Proposes Sale of 846,744 Shares of Common Stock | LYRA Stock News
Lyra Therapeutics files to sell 846,744 shares of common stock for holders
12 Health Care Stocks Moving In Friday's Intraday Session
Lyra Therapeutics Secures $4.3M in Direct Offering